An Antisense Drug Enters Testing Against BK Virus in Transplant Patients

Asahi Kasei Therapeutics has begun a Phase 2a clinical trial of AIC468, an investigational antisense drug designed to suppress BK virus replication in kidney transplant recipients. The company announced on October 8, 2026, that the first patient had received treatment, advancing the candidate from early-stage testing in healthy volunteers into a study involving patients with the viral infection.

The programme addresses an important unmet medical need: BK virus can reactivate in immunosuppressed patients following kidney transplantation, potentially damaging the transplanted organ.

Why BK Virus Is a Serious Concern After Kidney Transplantation

BK virus, also known as BK polyomavirus, is common in the general population and usually remains dormant without causing symptoms. However, medications used to prevent organ rejection suppress the immune system, allowing the virus to reactivate in some transplant recipients.

When the virus replicates in the transplanted kidney, it can cause BK virus-associated nephropathy, a condition that damages kidney tissue and may compromise graft function. In severe cases, patients can lose their transplanted kidney.

Current management commonly involves reducing immunosuppressive medication to help the patient's immune system control the infection. However, reducing immunosuppression can increase the risk of organ rejection, creating a difficult balance for transplant teams.

AIC468 is being developed as a targeted antiviral approach that could potentially address viral replication without relying solely on changes to immunosuppressive treatment. citeturn871310search0

How AIC468 Uses Antisense Technology

AIC468 is an antisense oligonucleotide (ASO), a short, laboratory-designed nucleic acid molecule intended to interfere with specific RNA processes.

The candidate targets the processing of BK virus early-gene pre-mRNA. By altering its splicing, AIC468 is designed to prevent the formation of messenger RNA that encodes the virus's large T antigen, a protein essential for viral replication.

This mechanism differs from approaches that broadly suppress immune activity. Instead, AIC468 aims to interfere directly with a process the virus needs to reproduce inside infected cells.

The approach has shown antiviral activity in preclinical research, while the Phase 1 study in healthy volunteers provided initial safety, tolerability and pharmacokinetic data. Whether these findings translate into meaningful reductions in viral levels and improved kidney outcomes must now be established in patients. citeturn871310search0turn871310search6

Phase 2a Trial to Assess Safety and Antiviral Activity

The new study, registered as NCT07503561, is randomized, double-blind and placebo-controlled. It forms part of a broader Phase 2/3 development programme evaluating AIC468 in adults with BK virus infection following kidney transplantation.

The initial Phase 2a portion is designed primarily to assess safety, tolerability and pharmacokinetics across multiple dose levels. Researchers will also examine changes in BK virus DNA levels in the blood to explore whether treatment produces an antiviral effect.

The planned study includes sequential dose cohorts, with participants assigned to AIC468 or placebo. Treatment is administered through weekly subcutaneous injections during a four-week treatment period, followed by continued monitoring.

Investigators will monitor adverse events, laboratory measurements and transplant-related outcomes, including possible graft rejection or loss. Viral measurements will help researchers assess whether the treatment lowers the amount of BK virus circulating in the blood.

The trial is an early patient-stage evaluation, so it is not yet designed to establish definitive evidence that AIC468 prevents kidney damage or improves long-term transplant survival. citeturn871310search1

What Earlier Testing Has Established

Before entering the patient trial, AIC468 underwent Phase 1 evaluation in healthy volunteers. According to the development programme's reported findings, treatment was generally well tolerated, with mild-to-moderate injection-site reactions among the reported effects and no evidence of antisense-related toxicity identified in that study.

These results supported progression into testing in kidney transplant recipients, whose medical circumstances differ substantially from those of healthy volunteers.

Safety will be especially important in this population because patients already receive immunosuppressive medicines and may be vulnerable to infections, kidney complications and organ rejection. Larger and longer studies will be required to characterize the drug's risks and determine whether it offers clinically meaningful benefits. citeturn871310search6turn871310search7

AIC468 and the Search for Targeted BK Virus Treatments

AIC468 is not the only experimental approach being investigated for BK virus infection. Researchers are also exploring antibody-based medicines and virus-specific immune-cell therapies.

For example, another investigational approach, posoleucel, uses donor-derived T cells directed against several viruses, including BK virus. A published Phase 2 study in kidney transplant recipients reported reductions in BK viral load, although the study's size and follow-up limited conclusions about definitive clinical outcomes. citeturn871310search3

AIC468 differs by targeting viral RNA processing rather than supplying virus-specific immune cells. These approaches reflect the range of strategies under investigation for a condition in which treatment options remain limited.

For drug developers, a targeted antiviral could offer a valuable addition to transplant care if it can reduce viral replication while maintaining an acceptable safety profile. For patients, the key question will be whether lowering viral levels translates into better preservation of transplanted kidney function.

What Comes Next for the Antisense Candidate

The Phase 2a study will provide the first important assessment of AIC468 in adults with BK virus infection after kidney transplantation. Results on safety, drug exposure and changes in viral load will help determine the next steps in development.

Further trials will need to establish whether the treatment can produce sustained antiviral effects, reduce the risk of BK virus-associated nephropathy and protect graft function without increasing the likelihood of rejection.

For now, AIC468 remains investigational, and no efficacy benefit in transplant patients has yet been established by the newly initiated study. Its progression into patient testing marks a development milestone, but its role in clinical practice will depend on the results of subsequent trials.

Sources:

https://www.aktx.com/en/news/asahi-kasei-therapeutics-announces-first-patient-dosed-in-phase-2a-trial-of-aic468-for-bk-virus-infection-in-kidney-transplant-recipients/?